International Securities Identification Number

ARTEX MTF AG : Francis Bacon to be the first artist traded on ARTEX

Retrieved on: 
Thursday, June 1, 2023
International Securities Identification Number, Work of art, Markets in Financial Instruments Directive 2014, Life, Commission, Clearstream, MTF, History, LSEG, Prospectus, II, Trust, Work, Offering, Rothschild & Co, Commission de Surveillance du Secteur Financier, Regulatory News Service, Initial public offering, SIX, Security (finance), Auction, Euroclear, Portrait, Issuer

ARTEX MTF AG (“ARTEX MTF” ― www.artex-stockexchange.com) announces that the first artwork to be admitted to trading is the ‘Three Studies for a Portrait of George Dyer’ (the “Artwork”), an oil on canvas triptych painted by British artist, Francis Bacon in 1963.

Key Points: 
  • ARTEX MTF AG (“ARTEX MTF” ― www.artex-stockexchange.com) announces that the first artwork to be admitted to trading is the ‘Three Studies for a Portrait of George Dyer’ (the “Artwork”), an oil on canvas triptych painted by British artist, Francis Bacon in 1963.
  • Prince Wenceslas of Liechtenstein, ARTEX Co-Founder and Chairman stated: “To offer a masterpiece by Francis Bacon as the first listing on ARTEX is a great privilege but also a responsibility.
  • Bacon is the first artist to be brought to the public by ARTEX.
  • UnaVista, an LSEG business, will support ARTEX in fulfilling its information exchange and reporting to the relevant supervisory bodies.

ARTEX MTF AG : Francis Bacon to be the First Artist Traded on ARTEX

Retrieved on: 
Wednesday, May 31, 2023
Arts, Museums, Entertainment, Professional Services, Finance, International Securities Identification Number, Work of art, Markets in Financial Instruments Directive 2014, Life, Commission, Clearstream, MTF, History, LSEG, Prospectus, II, Trust, Work, Offering, Rothschild & Co, Commission de Surveillance du Secteur Financier, Initial public offering, SIX, Auction, Security (finance), Euroclear, Portrait, Issuer

ARTEX MTF AG (“ARTEX MTF” ― www.artex-stockexchange.com ) announces that the first artwork to be admitted to trading is the ‘Three Studies for a Portrait of George Dyer’ (the “Artwork”), an oil on canvas triptych painted by British artist, Francis Bacon in 1963.

Key Points: 
  • ARTEX MTF AG (“ARTEX MTF” ― www.artex-stockexchange.com ) announces that the first artwork to be admitted to trading is the ‘Three Studies for a Portrait of George Dyer’ (the “Artwork”), an oil on canvas triptych painted by British artist, Francis Bacon in 1963.
  • Prince Wenceslas of Liechtenstein, ARTEX Co-Founder and Chairman stated: “To offer a masterpiece by Francis Bacon as the first listing on ARTEX is a great privilege but also a responsibility.
  • Bacon is the first artist to be brought to the public by ARTEX.
  • UnaVista, an LSEG business, will support ARTEX in fulfilling its information exchange and reporting to the relevant supervisory bodies.

 Horizon Therapeutics plc (“Horizon”) - Rule 2.12 Announcement

Retrieved on: 
Thursday, May 4, 2023
Biotechnology, General Health, Other Health, Health, Pharmaceutical, International Securities Identification Number, Treasury, Holding company, Security (finance)

In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on March 31, 2023, Horizon’s issued ordinary share capital is comprised of 228,576,339 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each.

Key Points: 
  • In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on March 31, 2023, Horizon’s issued ordinary share capital is comprised of 228,576,339 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each.
  • The Company has 384,366 Ordinary Shares which are held as treasury shares.
  • The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol “HZNP”.
  • The International Securities Identification Number for these securities is IE00BQPVQZ61.

ObsEva Announces Change of Central Securities Depositary

Retrieved on: 
Thursday, April 20, 2023
DTC, Depository Trust & Clearing Corporation, SIX Swiss Exchange, Depository Trust Company, Bangladesh Securities and Exchange Commission, ISIN, CUSIP, Security (finance), International Securities Identification Number, SIX

ObsEva intends to file a Form 15 with the Securities and Exchange Commission (the “SEC”) suspending its reporting obligations under Section 15(d) of the Exchange Act on April 26, 2023.

Key Points: 
  • ObsEva intends to file a Form 15 with the Securities and Exchange Commission (the “SEC”) suspending its reporting obligations under Section 15(d) of the Exchange Act on April 26, 2023.
  • As a result, ObsEva's common shares are expected to be no longer eligible to settle through the systems operated by The Depository Trust Company (“DTC”), which so far has operated as the central securities depositary for ObsEva's common shares.
  • ObsEva has taken steps to provide that SIX SIS AG (“SIX SIS”) will act as the central securities depositary for ObsEva's common shares.
  • SIX SIS is a central securities depositary for securities traded on SIX Swiss Exchange, where ObsEva's common shares are listed under the ticker symbol “OBSN”.

EQS-News: AIXTRON: New shares from stock option program with separate ISIN

Retrieved on: 
Friday, March 3, 2023
ISIN, Supervisory board, EUR, FSE, Exercise, Frankfurt Stock Exchange, Annual, Federal Executive Boards, International Securities Identification Number, Herzogenrath, Security (finance)

Herzogenrath, March 3, 2023 - AIXTRON SE (FSE: AIXA), a leading manufacturer of deposition equipment for the semiconductor industry, enabled employees to participate in the Company's share capital through stock option programs and, under the terms of the 2012 stock option program, eligible employees can currently exercise stock options at exercise prices ranging from EUR 13.14 to EUR 14.01.

Key Points: 
  • Herzogenrath, March 3, 2023 - AIXTRON SE (FSE: AIXA), a leading manufacturer of deposition equipment for the semiconductor industry, enabled employees to participate in the Company's share capital through stock option programs and, under the terms of the 2012 stock option program, eligible employees can currently exercise stock options at exercise prices ranging from EUR 13.14 to EUR 14.01.
  • The so-called "new shares" arising from the exercise of the above-mentioned options will receive a separate ISIN (International Securities Identification Number) and are not entitled to dividends for fiscal year 2022.
  • The new shares will be traded on the Frankfurt Stock Exchange from today under the ISIN DE000A32VP57 up to and including the date of the Annual General Meeting on May 17, 2023.
  • In view of the very positive business development in the past fiscal year, AIXTRON plans to pay a dividend again.

Horizon Therapeutics plc - Rule 2.12 Announcement

Retrieved on: 
Wednesday, March 1, 2023
General Health, Professional Services, Health, Finance, International Securities Identification Number, Treasury, Holding company, Security (finance)

In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on February 23, 2023, Horizon’s issued ordinary share capital is comprised of 228,832,390 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each.

Key Points: 
  • In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on February 23, 2023, Horizon’s issued ordinary share capital is comprised of 228,832,390 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each.
  • The Company has 384,366 Ordinary Shares which are held as treasury shares.
  • The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol “HZNP”.
  • The International Securities Identification Number for these securities is IE00BQPVQZ61.

Rule 2.12 Announcement – Horizon Therapeutics plc

Retrieved on: 
Thursday, January 12, 2023
Health, Other Health, Other Science, Research, Pharmaceutical, Science, Treasury, International Securities Identification Number, Holding company, Security (finance)

In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on January 11, 2023, Horizon’s issued ordinary share capital is comprised of 228,768,464 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each.

Key Points: 
  • In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”), Horizon confirms that, as of the close of business on January 11, 2023, Horizon’s issued ordinary share capital is comprised of 228,768,464 ordinary shares, nominal value $0.0001 per share (the “Ordinary Shares”) and 40,000 deferred ordinary shares of €1.00 each.
  • The Company has 384,366 Ordinary Shares which are held as treasury shares.
  • The Ordinary Shares are admitted to trading on the Nasdaq Global Select Market under the ticker symbol “HZNP”.
  • The International Securities Identification Number for these securities is IE00BQPVQZ61.

Horizon Therapeutics plc Confirms Preliminary Discussions Regarding Potential Offer

Retrieved on: 
Tuesday, November 29, 2022
Health, Other Health, Research, Pharmaceutical, Science, Biotechnology, Financial Conduct Authority, Autoimmunity, International Securities Identification Number, Science, Amgen, LLP, Inflammation, Cooley LLP, United Kingdom, Knowledge, Therapy, Patient, Common stock, Courage, Irish Takeover Panel, Morgan Stanley, Prudential Regulation Authority (United Kingdom), J.P. Morgan & Co., PRA, Treasury, Risk, Trustee, Failure, Prudential regulation, Horizon, Acquisition, Person, Holding company, Property management, Security (finance), Bank, Financial adviser, Sanofi

The Board of Horizon Therapeutics plc (Nasdaq: HZNP) (Horizon or the Company) confirms that it is engaged in highly preliminary discussions with Amgen Inc., Janssen Global Services, LLC and Sanofi (each a "Possible Offeror") which may or may not lead to an offer being made for the entire share capital of the Company.

Key Points: 
  • The Board of Horizon Therapeutics plc (Nasdaq: HZNP) (Horizon or the Company) confirms that it is engaged in highly preliminary discussions with Amgen Inc., Janssen Global Services, LLC and Sanofi (each a "Possible Offeror") which may or may not lead to an offer being made for the entire share capital of the Company.
  • Horizon Therapeutics plc is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases.
  • Any Horizon shareholder may request a copy of this announcement in hard copy form by writing to Investor Relations, Horizon Therapeutics plc, 70 St. Stephens Green, Dublin 2, D02 E2X4, Ireland, or by contacting Tina Ventura, Chief Investor Relations Officer by email to [email protected] .
  • Any written requests must include the identity of the Horizon shareholder and any hard copy documents will be posted to the address of the Horizon shareholder provided in the written request.

Magnit announces the exclusion of its bonds from the “First Level” section of the list of securities admitted to trading at Moscow Exchange due to their redemption

Retrieved on: 
Friday, May 6, 2022
Company, ISIN, International Securities Identification Number, LSE, Krasnodar, List, Exchange, MOEX, Moscow Exchange, Security (finance)

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Krasnodar, Russia (May 6, 2022): Magnit PJSC (MOEX and LSE: MGNT; the Company), one of Russias leading retailers, announces the exclusion of its bonds from the First Level Section of the List of securities admitted to trading at Moscow Exchange.
  • Please be informed that on May 5, 2022 exchange-traded bonds of the B-003-04 series were excluded from the First Level Section of the List of securities admitted to trading at Moscow Exchange, due to their redemption.
  • Non-convertible interest-bearing certified exchange-traded bonds to the bearer with the obligatory centralized custody of the B-003-04 series with identification number 4B02-04-60525-P-003P as of 29.10.2019, placed under the Exchange-traded bonds program with identification number 4-60525--003P-02E as of 30.01.2018, International Securities Identification Number (ISIN) RU000A100ZS3

Statement Regarding Possible Offer for Clipper Logistics plc

Retrieved on: 
Sunday, February 20, 2022
Depreciation, Risk, Financial adviser, Open position, Exchange, Compliance, Calendar, International Securities Identification Number, Financial Conduct Authority, EBIT, GXO, Uncertainty, COVID-19, Industry, London Stock Exchange, United Kingdom, IFRS, Sale, Nature, City Code on Takeovers and Mergers, Documentation, Person, Par value, Possibility, Pandemic, Securities Act of 1933, Disclosure, Forward-looking statement, Rothschild & Co, Takeover, Lists of disasters, Clipper, EBITDA, London, Silviculture, Security (finance), Health insurance, Holding company, Bloomberg, Numis

GREENWICH, Conn., and LONDON, Feb. 20, 2022 (GLOBE NEWSWIRE) -- The Boards of Clipper Logistics plc (“Clipper”) and GXO Logistics, Inc. (“GXO”) are pleased to announce that they have reached agreement on the key terms of a possible cash and share offer for Clipper by GXO (the “Possible Offer”).

Key Points: 
  • Any offer, if made, will be made solely by certain offer documentation which will contain the full terms and conditions of any offer, including details of how it may be accepted.
  • If GXO ultimately seeks to implement the transaction by way of a takeover offer, that offer will be made in compliance with applicable US laws and regulations.
  • The forward-looking statements contained in this document include statements relating to the expected effects of the Offer on Clipper and/or GXO, the expected timing and scope of the Offer, and other statements other than historical facts.
  • The following Clipper shareholders have given irrevocable undertakings to GXO to (i) vote in favour of the Possible Offer at any court meeting (or, in the event that the Possible Offer is implemented by way of a takeover offer rather than a scheme of arrangement, accept the takeover offer); and (ii) elect to receive 50 per cent.